Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eisai Inc.
NeoImmuneTech
Eli Lilly and Company
Eisai Inc.
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
Immatics US, Inc.
Essen Biotech
Essen Biotech
AstraZeneca
DualityBio Inc.
Ocellaris Pharma, Inc.
Jacobio Pharmaceuticals Co., Ltd.
GV20 Therapeutics
Palleon Pharmaceuticals, Inc.
NuCana plc
PharmaMar
Marengo Therapeutics, Inc.
Cancer Research UK
Numab Therapeutics AG
Novartis
AtlasMedx, Incorporated
Genelux Corporation
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Cyteir Therapeutics, Inc.
Aminex Therapeutics, Inc.
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc
Cancer Research UK
University of California, San Diego
Capital Medical University
CytomX Therapeutics
Kineta Inc.
Revolution Medicines, Inc.
Advaxis, Inc.
Genelux Corporation
Tesaro, Inc.
Kiadis Pharma
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NKGen Biotech, Inc.
Radboud University Medical Center
National Institutes of Health Clinical Center (CC)
University of Utah
Clavis Pharma
Instituto de Investigação em Imunologia
Hellenic Oncology Research Group
Hellenic Oncology Research Group
Adherex Technologies, Inc.
University of Plymouth